Peter Allen

Part of Neurocrine Biosciences, Inc., Diurnal Ltd. is a European, British UK-headquartered specialty pharmaceutical company founded in 2004. The company is based in Cardiff, UK. The company is dedicated to developing lifelong treatments for rare and chronic endocrine conditions.

Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom.

Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom.

Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

Inion Oy is a medical devices company focused on the development and commercialization of innovative biodegradable and bioactive implants for applications in Spine and Specialty Orthopedics applications. By targeting key strategic markets in the USA and select territories in the rest of the world, Inion has built a product portfolio sold through a dedicated network of specialist distributors. Inion's products include biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries, such as those caused by trauma or by reconstructive surgery. Inion's core expertise is in the design and manufacture of implants from its proprietary Inion Optima™ family of biomaterials, which enables the Company to develop medical implants with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation. Incorporated in 2000, Inion has offices in the UK and USA, and its head office, R&D and manufacturing facilities are in Tampere, Finland.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

Abacus Group Ltd. distributes connector, passive, electromechanical, power supply and battery products. It also provides contract manufacturing services which helps in making electronic equipment such as display peripherals. The company was founded in 1972 and is headquartered in Stevenage, the United Kingdom.

Inion Oy is a medical devices company focused on the development and commercialization of innovative biodegradable and bioactive implants for applications in Spine and Specialty Orthopedics applications. By targeting key strategic markets in the USA and select territories in the rest of the world, Inion has built a product portfolio sold through a dedicated network of specialist distributors. Inion's products include biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries, such as those caused by trauma or by reconstructive surgery. Inion's core expertise is in the design and manufacture of implants from its proprietary Inion Optima™ family of biomaterials, which enables the Company to develop medical implants with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation. Incorporated in 2000, Inion has offices in the UK and USA, and its head office, R&D and manufacturing facilities are in Tampere, Finland.

Abacus Group Ltd. distributes connector, passive, electromechanical, power supply and battery products. It also provides contract manufacturing services which helps in making electronic equipment such as display peripherals. The company was founded in 1972 and is headquartered in Stevenage, the United Kingdom.

Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom.

Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom.